title: The management of chronic viral hepatitis: a Canadian consensus conference 2004.
abstract: Several government and nongovernment organizations held a consensus conference on the management of acute and chronic viral hepatitis to update previous management recommendations. The conference became necessary because of the introduction of new forms of therapy for both hepatitis B and hepatitis C. The conference issued recommendations on the investigation and management of chronic hepatitis B, including the use of lamivudine, adefovir and interferon. The treatment of hepatitis B in several special situations was also discussed. There were also recommendations on the investigation and treatment of chronic hepatitis C and hepatitis C-HIV coinfection. In addition, the document makes some recommendations about the provision of services by provincial governments to facilitate the delivery of care to patients with hepatitis virus infection. The present document is meant to be used by practitioners and other health care providers, including public health staff and others not directly involved in patient care.
authors.affiliation: University of Toronto, Toronto, Ontario, Canada. morris.sherman@uhn.on.ca
authors.forename: Morris
authors.initials: M
authors.lastname: Sherman
authors.forename: Vincent
authors.initials: V
authors.lastname: Bain
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Villeneuve
authors.forename: Robert P
authors.initials: RP
authors.lastname: Myers
authors.forename: Curtis
authors.initials: C
authors.lastname: Cooper
authors.forename: Steven
authors.initials: S
authors.lastname: Martin
authors.forename: Catherine
authors.initials: C
authors.lastname: Lowe
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002170:Canada; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D012367:RNA, Viral / Q000032:analysis; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D018937:Hepatitis C Antibodies; D016898:Interferon-alpha; D063065:Organophosphonates; D012367:RNA, Viral; D014761:Viral Hepatitis Vaccines; D019259:Lamivudine; C053001:adefovir; D000225:Adenine